Biocon Biologics, an arm of biotechnology major Biocon, on Thursday said it has signed a pact with the Clinton Health Access Initiative (CHAI) to expand access to life-saving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership.
The partnershipis a significant step in delivering advanced cancer therapies to patients who need them themost and ensuring equitable access to high-quality biosimilars in low- and middle-incomecountries (LMICs), Biocon Biologics said in a statement.
Biocon Biologics willinitially supply biosimilar Trastuzumab and biosimilar Pegfilgrastim and will expand the arrangement to includeother biosimilars,it added.
Biocon Biologics Executive ChairpersonKiran Mazumdar-Shaw said, “The collaboration with CHAI further strengthens our resolve to address the unmet patient needs in Asia and Africa for advanced cancer therapies through cost effective alternatives to expensive reference biologics.”
This is an extension of “our commitment to enable universal access to cancer patients following the initiation of our Mission 10 cents to provide insulins for people with diabetes in LMICs”, she added.
In a similar vein, Biocon Biologics CEOChristiane Hamacher said the company is reimagining access to biologics in LMICs through strategic partnerships with globalhealth organisations.
“We are committed to reducing the high cost of cancer care forhealthcare systems through our biosimilars and are pleased to address the needs of patientsin Africa and Asia through the Cancer Access Partnership (CAP)”, she added.
Biocon Biologics is leveraging its science, scale and expertise to shift the access paradigm for patients in need of biosimilars across the globe, the statement said.
“Expanding the Cancer Access Partnership to include high quality biologics from Biocon takes us another step closer to ensuring that cancer patients have access to the quality medications that they need at an affordable price, no matter where they live”,CHAI CEO Ian Barton said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
